Empatab 25

Indications

Empatab is prescribed for:

• Assisting in glycemic control in adults with type 2 diabetes mellitus as part of a comprehensive plan, including diet and exercise.
• Reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus who have existing cardiovascular disease.

Use as directed by a registered healthcare provider.

Pharmacology

Empagliflozin, the active ingredient in Empatab, is a sodium-glucose co-transporter-2 (SGLT2) inhibitor. This medication works by blocking SGLT2, a protein responsible for the reabsorption of glucose in the kidneys. By inhibiting this protein, Empagliflozin promotes glucose excretion through urine, reducing blood glucose levels. It also supports weight loss and helps lower blood pressure, providing multiple benefits for patients managing type 2 diabetes.

Dosage & Administration

• The recommended starting dose of Empagliflozin is 10 mg once daily, preferably taken in the morning, with or without food.
• If the patient tolerates this dose, it may be increased to 25 mg once daily.
• In patients with dehydration or low blood volume, it is advised to correct this condition before starting Empagliflozin.

Consult a registered healthcare provider for personalized dosing recommendations.

Interactions

• Diuretics: When taken with diuretics, Empatab may increase urine output.
• Insulin or Insulin Secretagogues: Concurrent use with insulin or insulin secretagogues may elevate the risk of hypoglycemia (low blood sugar).
• Urine Glucose Test: SGLT2 inhibitors like Empagliflozin can result in positive urine glucose tests due to increased glucose excretion. It is recommended to use alternative methods to monitor glycemic control.
• 1,5-AG Assay: The 1,5-AG assay is not reliable for monitoring blood glucose levels in patients using SGLT2 inhibitors. Alternative methods should be considered for monitoring glycemic control.

Contraindications

Empagliflozin is contraindicated for patients who have:

• A history of severe hypersensitivity to Empagliflozin or any of its components.
• Severe renal impairment, end-stage renal disease, or those undergoing dialysis.

Side Effects

Common side effects of Empatab include:

• Urinary tract infections
• Female genital mycotic infections
• Dehydration
• Low blood pressure
• Weakness
• Dizziness
• Increased thirst

Pregnancy & Lactation

• There are no well-controlled studies on the use of Empagliflozin during pregnancy. It should be used only if the potential benefits outweigh the risks to the fetus.
• It is unknown if Empagliflozin passes into breast milk. It is not recommended for use during breastfeeding.

Precautions & Warnings

• Renal function should be assessed before starting Empatab and periodically during treatment.
• Empatab should not be initiated in patients with an estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m².
• No dosage adjustment is required for patients with an eGFR of 45 mL/min/1.73 m² or higher.

Overdose Effects

In case of overdose, supportive treatment should be initiated, including removal of unabsorbed material from the gastrointestinal tract and clinical monitoring. The removal of Empagliflozin through hemodialysis has not been studied.

Therapeutic Class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

• Store in a cool, dry place (below 30°C), away from light and moisture.
• Keep out of reach of children.